Ghassan K. Abou-Alfa, MD:Another important factor in regard to the TACE, which even I would like to stress because this is a critical one, is patients with metastatic disease should not receive local therapy. There are exceptions to the rules for certain reasons, but, in general, they should not receive systemic therapy in the setting of metastatic disease. Because the argument that the disease is probably more responsible for outcome of patients, based on what’s in the liver and not outside the liver, is not necessarily true. We have seen situations, unfortunately, where the disease can worsen outside the liver and can cause certain impact in regard to patient outcome, simply because there was no systemic therapy applied and it was all focused on local therapy. The fact that worrying about the disease in the liver is more important than anything else is not really the case. It’s something to keep in mind.
Let’s assume this patient had the same scenario but with 1 caveat or difference where the major blood vessel, let’s say the portal vein, isn’t involved with the cancerin other words, a tumor thrombus in the portal vein. TACE might not become a feasible option because, remember, TACE depends on the 2 blood flows that are available to the liver; ie, when we embolize on the arterial phase, we are dependent on the venous phase to allow the nourishment of the liver. And, as such, the venous part, which is a portal vein, is blocked. There’s a jeopardy to the liver over here.
Another approach would be possibly Yttrium-90 or radioembolization. There are lots of data that have shown it to be effective in the setting of portal vein thrombosis. Obviously, systemic therapy could be another appropriate option. Which one versus which, there are data that will be coming out at some point in time that probably would help guide us better for an option of that nature.
Transcript edited for clarity.
May 2015
February 2017
Hope Beyond Surgery: Optimizing Care for Cholangiocarcinoma
February 15th 2024In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.
Read More
Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC
February 6th 2024In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
Read More
Regorafenib Discontinuation More Likely With Poor Liver Function in Liver Cancer
January 19th 2024Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.
Read More